Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT06161441

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC

Sponsor: Regeneron Pharmaceuticals

Conditions Resectable Non-small Cell Lung Cancer

Interventions Carboplatin Cemiplimab Cisplatin Fianlimab Paclitaxel Pemetrexed Placebo

Updated 16 times since 2024 Last updated: Jan 9, 2026 Started: Jul 16, 2024 Primary completion: Apr 17, 2026 Completion: Nov 4, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06161441, this PHASE2 trial focuses on Resectable Non-small Cell Lung Cancer and remains ongoing. Sponsored by Regeneron Pharmaceuticals, it has been updated 16 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

16 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2

▶ Show 11 earlier versions

Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE2
Apr 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals

Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Alessandria, Italy , Ankara, Turkey (Türkiye) , Aviano, Italy , Barcelona, Spain , Bari, Italy , Batumi, Georgia , Bergamo, Italy , Bordeaux, France , Bornova, Turkey (Türkiye) and 84 more locations